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Summary
Background: Human immunodeﬁciency virus (HIV) is an important risk factor for the
global incidence and mortality of tuberculosis (TB) and has had a tremendous impact
on the epidemiology and the control of the disease. The purpose of this study was to
determine the demographic, laboratory and clinical characteristics of HIV-positive
TB cases in Canada as compared to HIV-negative cases.
Methods: TB cases reported to the Canadian TB Reporting System (CTBRS) from 1997
to 2006 were retrospectively reviewed and for those with known HIV serostatus,
the distributions of age, sex, country of birth, smear and culture positivity, drug
resistance, site of disease and treatment outcome were compared.
Results: 2710 TB cases had a report of an HIV test with a 12.9% positivity rate.
HIV-positive cases were more likely to be 30—44 years old, male, Canadian born non-
Aboriginal or African born. Sputum and lymph node biopsies were signiﬁcantly more
likely to be smear-positive and sputum was more likely to be culture positive. Anti-
TB drug resistant rates were similar, except for lower streptomycin resistance in new
HIV-positive cases. HIV-positive cases were signiﬁcantly more likely to present with
miliary or central nervous system TB, to have multi-system disease, to have lower
treatment success rates (66.4% versus 88.5%) and to have a 5.6 higher case-fatality
rate.
Interpretation: HIV-positive cases have a different demographic proﬁle, present with
more advanced and severe forms of disease, have poorer treatment outcomes and
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higher mortality. All TB cases should be tested for HIV so as to offer appropriate case
management and treatment.
dulaziz University for Health Sciences. Published by Elsevier
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Among 2360 HIV-negative TB cases, 2113 cases
had record of a smear microscopy test and 1023
cases were smear-positive, resulting in a smear-
positive detection rate of 48.4%. Among the 350© 2009 King Saud Bin Ab
Ltd. All rights reserved.
ntroduction
IV is an important risk factor for the global inci-
ence and mortality of tuberculosis (TB) and has
ad a tremendous impact on the epidemiology and
he control of the disease. In 2007, among the 9.3
illion new TB cases worldwide, an estimated 15%
ere HIV-positive. Of the 1.8 million TB deaths
eported, 26% were HIV-positive [1].
Since the 1940s the TB incidence rate in Canada
as been declining. In 2007, it was 4.7 per 100,000
opulation with a total of 1,548 cases of new
ctive and relapsed TB reported [2]. Further, it has
een estimated that in Canada, 2300—4500 new HIV
nfections occurred in 2005 and 58,000 persons lived
ith HIV infection at the end of the same year [3].
ecommendations for the screening of all TB cases
or HIV and for determining the TB status for all
IV-positive individuals have existed in Canada for
everal years; however, uptake and application of
hese guidelines are not universal [4,5]. In a previ-
us review of all TB cases reported to the Canadian
B Reporting System (CTBRS) for 1997 and 1998,
he extent of recorded HIV testing was assessed at
1.5% and the HIV infection prevalence among TB
ases with known HIV test results was 14.7% [4].
etween 1997 and 2006, the proportion of TB cases
or which HIV status was known within the CTBRS
ncreased from 5.6% to 27.2% [2]. The present study
urther explores the demographic, laboratory and
linical characteristics of HIV-positive cases as com-
ared with HIV-negative cases.
ethods
he CTBRS is a prospective database containing
emographic, clinical and laboratory information
or all cases of TB reported in Canada since 1970.
ases within the CTBRS meet the TB case deﬁnition
s per the Canadian Tuberculosis Standards [6]. The
TBRS has been collecting information on HIV sta-
us among TB cases since 1997. The present study
eviewed TB cases with a report of an HIV test result
rom 1997 to 2006. TB cases with a known HIV test
esult were divided into two groups: HIV-positive
nd HIV-negative and the following characteristics
ere compared: demographic characteristics (age,
n
a
iex, country of birth); the results of laboratory
esting (smear microscopy and culture results for
putum, bronchial wash, gastro intestinal wash,
ymph node biopsy, urine, cerebral spinal and
ther); diagnostic criteria (laboratory conﬁrmed or
linical diagnosis); primary drug resistance (isoni-
zid (INH), rifampacin (RMP), pyrazinamide (PZA),
thambutol (EMB) and streptomycin (SM))1; site of
isease (International Classiﬁcation of Diseases ver-
ion 9-ICD); treatment regimen (number and type of
rugs); and treatment outcome as per WHO guide-
ines [7].
Pearson’s 2 test and Fisher’s exact test were
sed to evaluate differences in proportions for the
ariables between the two groups; the means were
ompared using the Student’s t test. A P value of
ess than 0.05 was considered as statistically sig-
iﬁcant. Statistical analyses were conducted using
PSS v. 14.0 and Epi InfoTM 6.
esults
etween January 1997 and December 2006 a total
f 17 283 TB cases were reported to the CTBRS, of
hich 2975 (17.2%) had a report of an HIV test. A
roportion of the HIV status data (295) is submit-
ed to the CTBRS in aggregate, therefore analysis is
ased on 2710 cases with case level reporting.
Among the TB cases with HIV status reported,
50 (12.9%) were HIV-positive. HIV-positive TB cases
ere signiﬁcantly more likely to be between the
ges of 30—44 and more likely to be male than
IV-negative cases. Canadian-born Aboriginal Peo-
les were less likely to be HIV-positive than other
anadian-born cases. Among immigrants with TB
isease, HIV-positive cases were more likely to be
rom the African continent but less likely to be from
sia (Table 1).1 In the present study, the ﬁrst-line anti-TB drugs included iso-
iazid, rifampin, pyrazinamide, ethambutol and streptomycin,
lthough streptomycin has been considered a second-line drug
n Canada since 2005.
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Table 1 Demographic characteristics of TB cases in Canada by HIV status: 1997—2006.
Characteristics HIV-negative HIV-positive Chi P
n % n %
Age (year)
<15 53 2.2 6 1.7 181.7 0.000
15—29 626 26.7 49 14.0
30—44 629 26.5 209 59.7
45—59 485 20.6 69 19.7
60—74 356 15.1 16 4.6
≥75 211 8.9 1 0.3
Sex
F 1046 44.3 118 33.7 14.0 0.000
M 1314 55.7 232 66.3
Country of birth
Canada 960 40.7 199 56.9 57.6 0.000
Aboriginal 672 70.0 109 54.8
Non-Aboriginal 288 30.0 90 45.2
Subtotal 960 100.0 199 100.0
Foreign country 1392 59.0 148 42.3
Africa 162 11.6 75 50.7
Asia 1093 78.5 38 25.7
Europe 81 5.8 10 6.8
America 36 2.6 11 7.4
Oceania 9 0.6 2 1.4
Unknown 11 0.8 12 8.1
Subtotal 1392 100.0 148 100.0
Unknown 8 0.3 3 0.9
First episode of TB/
Yes 2142 90.1 325 92.9 8.44 0.01
No 214 9.1
Unknown 4 0.2
HIV-positive TB patients, 321 had isolates submitted
for smear microscopy and 203 of these were smear-
positive, for an overall smear-positive detection
rate of 63.2%, signiﬁcantly higher than HIV-negative
cases (Table 2). The smear-positive detection rates
of sputum and lymph node biopsy and other
samples among HIV-positive cases were all signiﬁ-
Table 2 Comparison of results of smear microscopy
and culture between HIV-negative and -positive cases.
Lab test HIV-negative HIV-positive Chi P
n % n %
Smear
Negative 1090 51.6 118 36.8
Positive 1023 48.4 203 63.2 23.5 0.00
Total 2113 100.0 321 100.0
Culture
Negative 189 8.5 22 6.5
Positive 2041 91.5 319 93.5 1.61 0.21
Total 2230 100 341 100
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antly higher than those among HIV-negative cases.
owever, there were no statistically signiﬁcant dif-
erences in the smear-positive detection rates of
ronchial wash, gastrointestinal (GI) wash, urine
nd cerebral spinal ﬂuid samples between HIV-
ositive cases and HIV-negative cases (Table 3).
2230 HIV-negative cases were culture tested for
ycobacterium tuberculosis and 2041 of these were
ulture-positive. Of the 341 HIV-positive cases,
19 cases were culture-positive. The resulting cul-
ure positive case detection rate for HIV-positive
ases was 93.5%, which was higher than that
mong HIV-negative cases, but this difference
as not statistically signiﬁcant (Table 2). How-
ver, among HIV-positive cases, the culture-positive
ase detection rate from sputum was 90.7% which
as signiﬁcantly higher than (84.3%) among HIV-
egative cases (Table 4).
The proportions of ﬁrst-line TB drug resistance,
hich were categorized as resistance to any one
rug (INH, RMP, PZA, EMB and SM) or multi-drug
esistant (MDR), in HIV-positive cases without a his-
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Table 3 Comparison of smear-positivity detection rates between HIV-negative and -positive cases.
Sample HIV-negative HIV-positive Chi P
n % n %
Sputum
Negative 863 52.0 103 41.4
Positive 797 48.0 146 58.6 9.77 0.00
Total 1660 100.0 249 100.0
Bronchial wash
Negative 155 61.8 27 50.9
Positive 96 38.2 26 49.1 2.13 0.14
Total 251 100.0 53 100.0
GI wash
Negative 90 86.5 6 85.7
Positive 14 13.5 1 14.3 1.00
Total 104 100.0 7 100.0
Lymph node biopsy
Negative 111 71.6 11 39.3
Positive 44 28.4 17 60.7 11.15 0.00
Total 155 100.0 28 100.0
Urine
Negative 75 83.3 14 87.5
Positive 15 16.7 2 12.5 1.00
Total 90 100.0 16 100.0
Cerebral spinal ﬂuid
Negative 22 91.7 9 90.0
Positive 2 8.3 1 10.0 1.00
Total
Othera
Negative 230 59.0 28 40.0
Positive 160 41.0 42 60.0 8.68 0.00
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2003—2005 [8]. In the present study, 12.9% of cases
who had a HIV test reported were positive, simi-Total 390 100.0
a Includes samples of unknown origin.
ory of previous TB disease were 8.8% and 0.3%,
espectively, lower than rates among HIV-negative
ases without previous TB history. However, with
he exception of SM resistance this difference
as not statistically signiﬁcant. The rate of drug
esistance in HIV-positive cases with a previous
B history was 19.0%, higher than that found in
elapsed or re-treatment HIV-negative cases, but
gain this difference was not statistically signiﬁcant
Table 5).
Among HIV-positive cases, the proportions of mil-
ary and central nervous system (CNS) TB were
7.4% and 4.6%, respectively, which were signiﬁ-
antly higher than the presentation of miliary and
NS TB among HIV-negative cases. HIV cases were
ore likely to have TB in two or more disease sites
nd the proportion of HIV-positive cases with pul-
onary and extra-pulmonary TB was three times
reater than among HIV-negative cases. Treatment
utcomes were signiﬁcantly different between HIV-
l
r70 100.0
ositive and negative cases. The rate of successful
reatment was lower for HIV-positive cases and the
ortality rate was signiﬁcantly higher (Table 6).
iscussion
n Canada, despite the long standing recommenda-
ion for routine HIV testing of all TB cases, only
7.2% TB cases had a report of an HIV test in the
TBRS for the period 1997—2006. This is far lower
han the proportion of reported HIV status in the
nited States, where HIV test results were avail-
ble for two-thirds of all TB cases for the years
2ar to a U.S. report in 2005 where the HIV-positive
ate among cases with known HIV status was 13%,
2 Study did not include data from California.
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Table 4 Comparison of culture-positivity detection rates between HIV-negative and -positive cases.
Sample HIV-negative HIV-positive Chi P
n % n %
Sputum
Negative 259 15.7 23 9.3
Positive 1388 84.3 224 90.7 6.97 0.01
Total 1647 100.0 247
Bronchial wash
Negative 24 9.6 4 7.5
Positive 227 90.4 49 92.5 0.79
Total 251 100.0 53 100.0
GI wash
Negative 44 43.6 2 25.0
Positive 57 56.4 6 75.0 0.46
Total 101 8
Lymph node biopsy
Negative 20 11.7 2 5.3
Positive 151 88.3 36 94.7 0.38
Total 171 100.0 38 100.0
Urine
Negative 47 48.5 7 28.0
Positive 50 51.5 18 72.0 3.37 0.07
Total 97 100.0 25 100.0
Cerebral spinal ﬂuid
Negative 10 38.5 3 21.4
Positive 16 61.5 11 78.6 0.32
Total 26 100.0 14 100.0
Othera
Negative 49 9.1 6 5.6
Positive 489 90.9 102 94.4 1.46 0.22
Total 538 100.0 108 100.0
a Includes samples of unknown origin.
Table 5 Comparison of results of drug susceptibility testing between HIV-negative and -positive cases.
DST HIV-negative HIV-positive Chi P
n % n %
New cases 1848 295
Any resistance
Resistance to EMB 23 1.2 6 2.0 1.19 0.28
Resistance to INH 112 6.0 14 4.7 0.79 0.37
Resistance to PZA 21 1.1 1 0.3 1.59 0.21
Resistance to RMP 16 0.9 4 1.4 0.66 0.42
Resistance to SM 95 5.1 5 1.7 6.64 0.01
MDR 15 0.8 1 0.3 0.71
Resistance to any drug 185 9.9 26 8.8 0.41 0.52
Cases with past history of TB 189 21
Resistance to EMB 4 2.1 0 0.0 — —
Resistance to INH 22 11.6 0 0.0 — —
Resistance to PZA 3 1.6 0 0.0 — —
Resistance to RMP 7 3.7 4 19.0 0.13 0.72
Resistance to SM 14 7.4 0 0.0 — —
MDR 7 3.7 0 0.0 — —
Resistance to any drug 29 15.3 4 19.0 0.75
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Table 6 Comparison of clinical characteristics between HIV-negative and -positive cases.
Clinical characteristics HIV-negative HIV-positive Chi P
n % n %
Site of disease (all) 2360 350
Pulmonary 1613 68.3 255 72.9 2.9 0.09
Primary 61 2.6 4 1.1 2.71 0.10
Other respiratory 247 10.5 39 11.1 0.15 0.70
Respiratory 1819 77.1 273 78.0 0.1 0.70
Miliary 55 2.3 61 17.4 169.6 0.00
CNS 36 1.5 16 4.6 15.0 0.00
Peripheral lymph node 350 14.8 55 15.7 0.2 0.67
Genitourinary system 63 2.7 15 4.3 2.9 0.09
Bones and joints 70 3.0 6 1.7 1.8 0.19
Intestines, peritoneum and mesenteric glands 69 2.9 15 4.3 1.9 0.17
Other sites 67 2.8 23 6.6 13.2 0.00
Distribution of disease sites
Only pulmonary 1415 60.0 166 47.4 93.8 0.00
Only extra-pulmonary 747 31.7 95 27.1
Pulmonary and extra-pulmonary 198 8.4 89 25.4
Number of disease sites
1 2213 93.8 266 76.0 137.8 0.00
2 126 5.3 60 17.1
≥3 21 0.9 24 6.9
Treatment outcome
Successful treatment 1825 88.5 178 66.4 158.9 0.00
Death 84 4.1 62 23.1
Transferred/lost to follow-up 43 2.1 7 2.6
Absconded 65 3.2 8 3.0
Failure or treatment ongoing 27 1.3 6 2.2
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The CTBRS allows for reporting of up to ﬁve disease sites, ther
cases reported.
ut far greater than the WHO estimate of a 5.7%
o-infection rate for Canada in 2007 [1,8]. Deter-
ining the true incidence of HIV-positive TB disease
or this period of time from the CTBRS is not possi-
le. HIV testing was likely biased towards those TB
ases with known risk factors for HIV infection. The
o-infection rate determined herein is considered
o be an overestimate, as all results in this study
pply only to those TB cases for which HIV status
s known and not necessarily to the remaining TB
ases for which there was no HIV report.
HIV infection has been shown to change the
ex and age distribution of TB. In Canada, there
as been an increase in the number of females
iving with HIV, with approximately 20% of all HIV-
ositive persons being female in 2005 [3]. The
resent study shows that males were predomi-
ant in both HIV-negative and HIV-positive cases,
ut also that two in three cases of HIV-positive
B were male, which was signiﬁcantly higher than
hat in HIV-negative cases. One study in Brazil
eported three-quarters of HIV-positive TB cases
T
A
a
i0.9 7 2.6
numbers in this table are greater than the actual number of
ere male [9]. Conversely, studies in Nigeria and
otswana showed that 57% and 55% HIV-positive TB
ases were male but with more male cases pre-
enting among the HIV-negative cohort (65% and
4%) [10,11]. Such different association between
ex and HIV-positive TB may be related to different
ex distributions of HIV/AIDS resulting from differ-
nt HIV transmission patterns in various regions.
he difference in the age distribution between HIV-
egative and positive in the present study was
imilar to previous reports [11]. For HIV-positive
B cases, the majority were reported among the
0—45-year-old age group (59.7%), whereas this age
roup represented only 26.5% of the HIV-negative
B cases.
The HIV infection rate among Aboriginal persons
as been estimated to be 2.8 times higher than
hat among non-Aboriginal persons in Canada [3].
he present study suggests that TB cases with
boriginal origin are less likely to be HIV-positive
nd therefore this higher rate of HIV positivity
s not manifesting among TB cases. One possible
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explanation of this may be selection bias with
respect to HIV testing.
HIV infection has had a considerable impact on
the TB epidemic globally, especially in areas like
sub-Saharan Africa where both prevalence rates
of HIV and TB are high. In some countries of this
region, it was reported that more than half of
TB cases were co-infected with HIV [10,12]. In
the present study, among TB cases born outside
Canada, cases born in Africa were more likely to
be HIV-positive. On the contrary, TB cases born
in Asia were less likely to be HIV-positive, most
certainly related to the nature and epidemiology
of the HIV epidemic in the country or region of
origin, with a higher prevalence of HIV among the
adult population in Africa [13].
Smear microscopy and culture testing are cru-
cial diagnostic tests for TB. It was reported that the
presence of HIV decreases the sensitivity of smear
microscopy, which leads to a lower smear-positive
rate among the HIV infected [10]. However in the
present study, smear-positivity was almost univer-
sally higher among HIV-positive cases.
The rates of drug resistance were not signif-
icantly different between HIV-positive and HIV-
negative groups, even among re-treatment cases.
This ﬁnding differs from a previous report of higher
primary drug resistance among HIV-positive TB
cases [14].
TB can almost attack any site of human body and
extra-pulmonary TB is known to be more common
among HIV-infected persons [15]. In this study, the
proportion of only pulmonary disease in HIV-positive
tuberculosis cases was signiﬁcantly reduced with
HIV cases presenting more often with both pul-
monary and extra-pulmonary disease. However,
the proportion of cases presenting with pulmonary
and extra-pulmonary disease among HIV-positive TB
cases (25.4%) was lower than that made in pre-
vious reports. Multi-site disease (pulmonary and
extra-pulmonary) accounted for 49% of all HIV-
positive cases in Brazil 49% and 35% in New York
[9,16]. In India, extra-pulmonary TB alone consti-
tuted 45—56% of all cases in persons with AIDS [17].
Miliary TB was the most common form of extra-
pulmonary TB among HIV-positive cases in the
present study. Other studies have also found an
increased presentation of miliary TB among HIV-
positive cases as compared to HIV-negative cases
[12,18,19]. However, in some studies, the propor-
tion of miliary TB in HIV-positive cases was very
low: 0.7% in Lusaka, Zambia, 1.4% in Karonga,
Zambia and 3.3% in Ethiopia [12,20]. The inci-
dence of TB among HIV-positive cases correlates
with the degree of impairment of cell-mediated
immunity. Therefore, when an HIV-positive case
RG.J. Wang et al.
ecomes immunosuppressed, TB is more likely to
isseminate. One report has suggested that among
mmunosuppressed TB cases, as many as 38% will
evelop disseminated disease [21]. The stage of
IV/AIDS development may be the main reason
or this difference in miliary TB incidence. Previ-
us studies have reported lymph node TB as being
he most frequent site of disease among those co-
nfected with HIV [17]. In the present study periph-
ral lymph node TB was the second most common
ite of disease in HIV-positive cases, but was not sig-
iﬁcantly different than the presentation of lymph
ode TB among HIV-negative cases. However, CNS
B was more 3.1 times more likely to present among
IV-positive cases. Previously published studies
iverge on the presentation of CNS TB among
IV-positive patients from one report indicating a
vefold increase in the presentation of CNS TB [17]
o no signiﬁcant difference [18,19]. A study in Brazil
ound that the highest proportion of HIV counseling
nd testing (screening) (74%) was observed among
ases with miliary TB, followed by those with TB
eningitis (65%) and lymphatic (57%) [22].
HIV infection modiﬁes the clinical presentation
f TB disease and makes treatment more difﬁcult
10]. Treatment completion rates were signiﬁcantly
ower among the HIV-positive cohort in this study.
he death rate in HIV-positive cases was 23.1%,
hich was 5.6 times higher that that of HIV-negative
ases, similar to a previous U.S. report [8]. Know-
ng that HIV infection is a risk factor for poorer
reatment outcomes, including death, should pro-
ide a strong clinical motivation to know the HIV
tatus of all TB patients. Universal HIV testing of TB
ases and reporting of these results are essential for
he delivery of the most effective treatment, care
nd prevention programs. The low proportion of TB
ases with a record of an HIV test in the present
tudy represents a lost opportunity in terms of iden-
ifying unrecognized HIV infection, improving the
utcome of TB treatment, offering counseling to
educe further transmission of HIV and assessing the
eed for antiretroviral medication.
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